Proportion of extended-spectrum ß-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Lonchel, Carine M ^a   Meex, Cécile ^a   Gangoué Piéboji, Joseph ^b   Boreux, Raphaël ^a   Assoumou, Marie Claire O ^c   Melin, Pierrette ^a   De Mol, Patrick ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CRPMT   (Cameroon)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; NITROFURANTOIN; TEMOCILLIN; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM ISOLATE; CAMEROON; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DRUG USE; ENZYME SYNTHESIS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT; POLYMERASE CHAIN REACTION; RISK FACTOR; CHEMISTRY; COMMUNICABLE DISEASE; DNA SEQUENCE; DRUG UTILIZATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; FECES; GENETICS; HETEROZYGOTE; HUMAN EXPERIMENT; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SECRETION; STATISTICS;

ADULT; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CAMEROON; CARRIER STATE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG UTILIZATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FECES; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OUTPATIENTS; POLYMERASE CHAIN REACTION; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84859969560     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-53     Document Type: Article

References (34)

1. Colodner R, Raz R. Extended-spectrum beta-lactamases: the end of cephalosporins?. Isr Med Assoc J 2005, 7(5):336-338.
2. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14(4):933-951. table of contents, 10.1128/CMR.14.4.933-951.2001, 89009, 11585791.
3. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004, 23:163-167. 10.1007/s10096-003-1084-2, 14986159.
4. Tandé D, Jallot N, Bougoudogo F, Montagnon T, Gouriou S, Sizun J. Extended-spectrum-beta-lactamase-producing Enterobacteriaceae in a Malian orphanage. Emerging Infectious Diseases 2009, 15:472-474. 10.3201/eid1503.071637, 2681105, 19239768.
5. Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004, 42(10):4769-4775. 10.1128/JCM.42.10.4769-4775.2004, 522353, 15472339.
6. Ho PL, Poon WW, Loke SL, Leung MS, Chow KH, Wong RC, Yip KS, Lai EL, Tsang KW. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women. J Antimicrob Chemother 2007, 60(1):140-144. 10.1093/jac/dkm144, 17496058.
7. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pérez-Cano R, Pascual A. Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia col in Nonhospitalized Patients. Journal of Clinical Microbiology 2004, 42:1089-1094. 10.1128/JCM.42.3.1089-1094.2004, 356843, 15004058.
8. Kader AA, Kamath KA. Faecal carriage of extended-spectrum ß-lactamase-producing bacteria in the community. Eastern Mediterranean Health Journal 2009, 15:1365-1370.
9. Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK. J Antimicrob Chemother 2004, 54(3):628-633. 10.1093/jac/dkh397, 15294889.
10. Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ. Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community. Antimicrob Agents Chemother 2008, 52(10):3814-3816. 10.1128/AAC.00877-08, 2565870, 18663030.
11. Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, Di Maggio T, Gamboa H, Gotuzzo E, Kronvall G, Paradisi F, Rossolini GM. Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob Agents Chemother 2007, 51(8):2720-2725. 10.1128/AAC.00026-07, 1932529, 17548490.
12. Tian SF, Chen BY, Chu YZ, Wang S. Prevalence of rectal carriage of extended-spectrum beta-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008, 54(9):781-785. 10.1139/W08-059, 18772941.
13. Gangoue-Pieboji J, Bedenic B, Koulla-Shiro S, Randegger C, Adiogo D, Ngassam P, Ndumbe P, Hachler H. Extended-spectrum-beta-lactamase-producing Enterobacteriaceae in Yaounde, Cameroon. J Clin Microbiol 2005, 43(7):3273-3277. 10.1128/JCM.43.7.3273-3277.2005, 1169189, 16000447.
14. Ahoyo AT, Baba-Moussa L, Anago AE, Avogbe P, Missihoun TD, Loko F, Prevost G, Sanni A, Dramane K. Incidence of infections due to Escherichia coli strains producing extended spectrum betalactamase, in the Zou/Collines Hospital Centre (CHDZ/C) in Benin. Med Mal Infect 2007, 37(11):746-752. 10.1016/j.medmal.2007.03.004, 17434702.
15. Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N. Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis 2005, 5:86. 10.1186/1471-2334-5-86, 1274314, 16225701.
16. Gangoue-Pieboji J, Miriagou V, Vourli S, Tzelepi E, Ngassam P, Tzouvelekis LS. Emergence of CTX-M-15-producing enterobacteria in Cameroon and characterization of a blaCTX-M-15-carrying element. Antimicrob Agents Chemother 2005, 49(1):441-443. 10.1128/AAC.49.1.441-443.2005, 538870, 15616331.
17. Fam N, Leflon-Guibout V, Fouad S, Aboul-Fadl L, Marcon E, Desouky D, El-Defrawy I, Abou-Aitta A, Klena J, Nicolas-Chanoine MH. CTX-M-15-producing Escherichia coli clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings. Microb Drug Resist 2011, 17(1):67-73. 10.1089/mdr.2010.0063, 21128836.
18. Peirano G, van Greune CH, Pitout JD. Characteristics of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli from community hospitals in South Africa. Diagn Microbiol Infect Dis 2011, 69(4):449-453. 10.1016/j.diagmicrobio.2010.11.011, 21396544.
19. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988, 10(4):867-878. 10.1093/clinids/10.4.867, 3263690.
20. CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, CLSI document M100-S20 2010, Wayne, PA: Clinical and Laboratory Standards Institute, CLSI.
21. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010, 65(3):490-495. 10.1093/jac/dkp498, 20071363.
22. Pagani L, Dell'Amico E, Migliavacca R, D'Andrea MM, Giacobone E, Amicosante G, Romero E, Rossolini GM. Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol 2003, 41(9):4264-4269. 10.1128/JCM.41.9.4264-4269.2003, 193787, 12958255.
23. Hounsa A, De Mol P. Knowledge and perceptions of staff working in private dispensaries in Abidjan as regards bacterial resistance. Ann Pharm Fr 2009, 67(4):284-290. 10.1016/j.pharma.2009.05.003, 19596103.
24. Gangoue-Pieboji J, Koulla-Shiro S, Ngassam P, Adiogo D, Ndumbe P. Antimicrobial activity against gram negative bacilli from Yaounde Central Hospital, Cameroon. Afr Health Sci 2006, 6(4):232-235. 1832069, 17604512.
25. Sekhsokh Y, Chadli M, El Hamzaoui SA. Frequency and antibiotic susceptibility of bacteria identified in urine. Med Mal Infect 2008, 38(6):324-327. 10.1016/j.medmal.2008.02.003, 18395378.
26. Seid J, Asrat D. Occurrence of extended spectrum beta-lactamase enzymes in clinical isolates of Klebsiella species from Harar region, eastern Ethiopia. Acta Trop 2005, 95(2):143-148. 10.1016/j.actatropica.2005.05.009, 15993831.
27. Potz NA, Hope R, Warner M, Johnson AP, Livermore DM. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 2006, 58(2):320-326. 10.1093/jac/dkl217, 16735428.
28. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009, 53(7):2846-2851. 10.1128/AAC.00247-09, 2704701, 19380595.
29. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RH, Hiltz A, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003, 37(12):1643-1648. 10.1086/379709, 14689346.
30. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002, 46(8):2540-2545. 10.1128/AAC.46.8.2540-2545.2002, 127340, 12121930.
31. Levin BR. Minimizing potential resistance: a population dynamics view. Clin Infect Dis 2001, 33(Suppl 3):S161-S169.
32. Machado E, Coque TM, Canton R, Novais A, Sousa JC, Baquero F, Peixe L. High diversity of extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae from Portugal. J Antimicrob Chemother 2007, 60(6):1370-1374. 10.1093/jac/dkm381, 17913717.
33. Miro E, Mirelis B, Navarro F, Rivera A, Mesa RJ, Roig MC, Gomez L, Coll P. Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 2005, 56(6):1152-1155. 10.1093/jac/dki395, 16244084.
34. Drieux L, Brossier F, Duquesnoy O, Aubry A, Robert J, Sougakoff W, Lecso-Bornet M, Jarlier V. Increase in hospital-acquired bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli in a large French teaching hospital. Eur J Clin Microbiol Infect Dis 2009, 28(5):491-498. 10.1007/s10096-008-0656-6, 19002728.